Strengthening Families & Communities LLC Buys 196 Shares of Johnson & Johnson $JNJ

Strengthening Families & Communities LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.7% in the second quarter, HoldingsChannel.com reports. The firm owned 2,031 shares of the company’s stock after buying an additional 196 shares during the period. Strengthening Families & Communities LLC’s holdings in Johnson & Johnson were worth $337,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Apexium Financial LP increased its stake in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 2,310 shares in the last quarter. Avanza Fonder AB increased its stake in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares in the last quarter. Joel Isaacson & Co. LLC increased its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Finally, Absher Wealth Management LLC increased its stake in Johnson & Johnson by 1.2% during the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock valued at $35,752,000 after purchasing an additional 2,469 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JNJ. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Citigroup upped their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday. HSBC upped their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $190.66 on Monday. The company’s 50-day moving average is $178.48 and its 200 day moving average is $163.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.